Author:
Judy Rebecca L.,Reynolds Joanna L.,Jnah Amy J.
Abstract
Although a rare cause of neonatal seizures, inborn errors of metabolism (IEMs) remain an essential component of a comprehensive differential diagnosis for poorly controlled neonatal epilepsy. Diagnosing neonatal-onset metabolic conditions proves a difficult task for clinicians; however, routine state newborn screening panels now include many IEMs. Three in particular—pyridoxine-dependent epilepsy, maple syrup urine disease, and Zellweger spectrum disorders—are highly associated with neonatal epilepsy and neurocognitive injury yet are often misdiagnosed. As research surrounding biomarkers for these conditions is emerging and gene sequencing technologies are advancing, clinicians are beginning to better establish early identification strategies for these diseases. In this literature review, the authors aim to present clinicians with an innovative clinical guide highlighting IEMs associated with neonatal-onset seizures, with the goal of promoting quality care and safety.
Publisher
Springer Publishing Company
Reference41 articles.
1. Waters, D , Adeloye, D , Woolham, D , Wastnedge, E , Patel, S , Rudan, I . Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. J Glob Health . 2018;8(2). https://doi.org/10.7189/jogh.08.021102
2. Neonatal seizures as onset of Inborn Errors of Metabolism (IEMs): from diagnosis to treatment. A systematic review;Metab Brain Dis,2021
3. Metabolic epilepsy;Indian J Pediatr,2021
4. Sharma, S , Prasad, AN . Inborn errors of metabolism and epilepsy: current understanding, diagnosis, and treatment approaches. Int J Mol Sci . 2017;18(7). https://doi.org/10.3390/ijms18071384
5. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency;J Inherit Metab Dis,2020